Evidence map›Paper›PMID 32849530›Full record

ArticleFrontiers in immunology2020

Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1.

Amanda Agazio, Jennifer Cimons, Kristin M Shotts, Kejun Guo, Mario L Santiago, Roberta Pelanda, Raul M Torres

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. SARS-CoV-2 infection relaxes peripheral B cell tolerance.The Journal of experimental medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amanda AgazioDepartment of Immunology & Microbiology, University of Colorado, Aurora, CO, United States.
Jennifer CimonsDepartment of Immunology & Microbiology, University of Colorado, Aurora, CO, United States.
Kristin M ShottsDepartment of Immunology & Microbiology, University of Colorado, Aurora, CO, United States.
Kejun GuoDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Colorado, Aurora, CO, United States.
Mario L SantiagoDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Colorado, Aurora, CO, United States.
Roberta PelandaDepartment of Immunology & Microbiology, University of Colorado, Aurora, CO, United States.
Raul M TorresDepartment of Immunology & Microbiology, University of Colorado, Aurora, CO, United States.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

Research Training in Rheumatology INCLUDE Down Syndrome SupplementT32AR007534 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Kristine A. Kuhn · 1986 to 2026
$6.1M
Chemokine response in B cell development and functionR01AI052157 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TORRES, RAUL MARTIN · 2002 to 2017
$5.4M
Tolerance in Polyclonal and Oligoclonal Immune SystemsR01AI052310 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2003 to 2017
$5.0M
Humoral Immunity by Anergic B cellsR01AI136534 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TORRES, RAUL MARTIN · 2018 to 2022
$2.6M
APOBEC3/Rfv3 and Immunoglobulin Somatic HypermutationR01AI116603 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2016 to 2020
$2.5M
Studies of human B cell tolerance, from a humanized mouse model to human beingsR01AI124474 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2016 to 2020
$2.3M
Testing an alternative model of central B cell toleranceR21AI131639 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2017 to 2018
$428k
Tolerance in Polyclonal and Oligoclonal Immune SystemsR56AI052310 · NIAID · NATIONAL JEWISH HEALTH · PI PELANDA, ROBERTA · 2007 to 2007
$363k
NIAID NIH HHS R01 AI052157NIAID NIH HHS R01 AI052310NIAID NIH HHS R01 AI116603NIAID NIH HHS R01 AI124474NIAID NIH HHS R01 AI136534NIAID NIH HHS R21 AI131639NIAID NIH HHS R56 AI052310NIAMS NIH HHS T32 AR007534
6 · The paper itself

Abstract

Peripheral tolerance is essential for silencing weakly autoreactive B cells that have escaped central tolerance, but it is unclear why these potentially pathogenic B cells are retained rather than being eliminated entirely. Release from peripheral tolerance restraint can occur under certain circumstances (i.e., strong TLR stimulus), that are present during infection. In this regard, we hypothesized that autoreactive B cells could function as a reserve population that can be activated to contribute to the humoral immune response, particularly with pathogens, such as HIV-1, that exploit immune tolerance to avoid host defense. In this study, we identify a population of autoreactive B cells with the potential to neutralize HIV-1 and experimentally release them from the functional restrictions of peripheral tolerance. We have previously identified murine monoclonal antibodies that displayed autoreactivity against histone H2A and neutralized HIV-1

Indexed as

AutoimmunityAllergensAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAutoantigensB-LymphocytesCell LineChlorocebus aethiopsCOS CellsHemagglutinationHistonesHIV-1HIV InfectionsHost-Pathogen InteractionsHumansAllergensAntibodies, MonoclonalAntibodies, NeutralizingAutoantigensHistonesImmunoglobulin MReceptors, Antigen, B-CellToll-Like ReceptorsautoreactiveB cellsbnAbsH2AHIV-1peripheral tolerancepolyreactive

Identifiers

PMID32849530
PMCPMC7396680
OpenAlexW3045244389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.